[go: up one dir, main page]

MX2018009938A - Profarmacos de hormona paratiroidea (pth). - Google Patents

Profarmacos de hormona paratiroidea (pth).

Info

Publication number
MX2018009938A
MX2018009938A MX2018009938A MX2018009938A MX2018009938A MX 2018009938 A MX2018009938 A MX 2018009938A MX 2018009938 A MX2018009938 A MX 2018009938A MX 2018009938 A MX2018009938 A MX 2018009938A MX 2018009938 A MX2018009938 A MX 2018009938A
Authority
MX
Mexico
Prior art keywords
pth prodrugs
pth
prodrugs
pharmaceutical compositions
relates
Prior art date
Application number
MX2018009938A
Other languages
English (en)
Inventor
Zettler Joachim
Maitro Guillaume
Wegge Thomas
Cleemann Felix
Sprogøe Kennett
Krusch Mathias
Original Assignee
Ascendis Pharma Bone Diseases As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Bone Diseases As filed Critical Ascendis Pharma Bone Diseases As
Publication of MX2018009938A publication Critical patent/MX2018009938A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Marine Sciences & Fisheries (AREA)

Abstract

La presente invención se refiere a profármacos de PTH, composiciones farmacéuticas que comprenden estos profármacos de PTH y sus usos.
MX2018009938A 2016-03-01 2017-02-28 Profarmacos de hormona paratiroidea (pth). MX2018009938A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16158048 2016-03-01
EP16179294 2016-07-13
EP16191484 2016-09-29
EP17155839 2017-02-13
PCT/EP2017/054550 WO2017148883A1 (en) 2016-03-01 2017-02-28 Pth prodrugs

Publications (1)

Publication Number Publication Date
MX2018009938A true MX2018009938A (es) 2019-03-14

Family

ID=58185540

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009938A MX2018009938A (es) 2016-03-01 2017-02-28 Profarmacos de hormona paratiroidea (pth).
MX2022015755A MX2022015755A (es) 2016-03-01 2018-08-16 Profarmacos de hormona paratiroidea (pth).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022015755A MX2022015755A (es) 2016-03-01 2018-08-16 Profarmacos de hormona paratiroidea (pth).

Country Status (30)

Country Link
US (7) US20200276276A1 (es)
EP (2) EP4470613A3 (es)
JP (3) JP7059195B2 (es)
KR (4) KR20250044469A (es)
CN (2) CN115025239B (es)
AU (5) AU2017227962C1 (es)
BR (1) BR112018017091A2 (es)
CA (1) CA3015585C (es)
DK (1) DK3423103T3 (es)
ES (1) ES2993932T3 (es)
FI (2) FI3423103T3 (es)
FR (1) FR24C1045I2 (es)
HR (1) HRP20241591T1 (es)
HU (2) HUE069445T2 (es)
IL (3) IL301616B2 (es)
LT (2) LT3423103T (es)
MA (2) MA45277A (es)
MX (2) MX2018009938A (es)
MY (2) MY208384A (es)
NL (1) NL301298I2 (es)
NO (1) NO2025005I1 (es)
NZ (1) NZ745318A (es)
PL (1) PL3423103T3 (es)
RS (1) RS66250B1 (es)
RU (1) RU2747316C2 (es)
SG (1) SG11201806092TA (es)
SI (1) SI3423103T1 (es)
SM (1) SMT202400423T1 (es)
WO (1) WO2017148883A1 (es)
ZA (1) ZA201805705B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
EP4470613A3 (en) 2016-03-01 2025-03-12 Ascendis Pharma Bone Diseases A/S Pth prodrugs
NZ751969A (en) 2016-09-29 2023-04-28 Ascendis Pharma Bone Diseases As Dosage regimen for a controlled-release pth compound
EP4223309A1 (en) 2016-09-29 2023-08-09 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
MA46428B1 (fr) 2016-09-29 2025-02-28 Ascendis Pharma Bone Diseases A/S Composés de pth à libération contrôlée
EP4218795A3 (en) 2016-09-29 2023-08-30 Ascendis Pharma Bone Diseases A/S Pth compounds with low peak-to-trough ratios
EP3765061A4 (en) * 2018-03-16 2022-01-26 The General Hospital Corporation PARATHORMON-POLYPEPTIDE CONJUGATES AND METHODS OF USE
EP3773680A1 (en) * 2018-03-28 2021-02-17 Ascendis Pharma Oncology Division A/S Il-2 conjugates
AU2019270464B2 (en) 2018-05-18 2024-09-26 Ascendis Pharma Bone Diseases A/S Starting dose of PTH conjugates
US11634468B2 (en) 2019-01-29 2023-04-25 Shire-Nps Pharmaceuticals, Inc. Parathyroid hormone variants
MX2021009370A (es) * 2019-02-11 2021-09-10 Ascendis Pharma Bone Diseases As Formulaciones farmaceuticas liquidas de conjugados de hormona paratiroidea.
KR20220128390A (ko) * 2020-01-13 2022-09-20 아센디스 파마 본 디지즈 에이/에스 부갑상선기능저하증 치료
TW202210502A (zh) 2020-06-03 2022-03-16 丹麥商阿森迪斯腫瘤製藥有限公司 新穎il-2序列及其用途
TWI888383B (zh) * 2020-06-19 2025-07-01 丹麥商阿森迪斯藥物骨疾病股份有限公司 Ｐｔｈ綴合物的液體藥物製劑
WO2021263040A1 (en) * 2020-06-26 2021-12-30 Shire-Nps Pharmaceuticals, Inc. Stable peptibody formulations
AU2021319863A1 (en) 2020-08-05 2023-02-16 Ascendis Pharma A/S Conjugates comprising reversible linkers and uses thereof
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone
EP4611891A1 (en) 2022-11-02 2025-09-10 Ascendis Pharma Bone Diseases A/S Pth treatment regimen comprising two pth compounds
WO2025051711A1 (en) 2023-09-04 2025-03-13 Ascendis Pharma Bone Diseases A/S Pth treatment of chronic kidney disease
CN118638210B (zh) * 2024-08-14 2024-11-15 南方医科大学第三附属医院（广东省骨科研究院） 长效pth类似物的制备方法及应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744444A (en) * 1989-10-27 1998-04-28 Haemopep Pharma Gmbh HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
ZA9811127B (en) 1997-12-09 2000-07-11 Lilly Co Eli Stabilized teriparatide solutions.
US6624142B2 (en) 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US20050124537A1 (en) 2000-04-27 2005-06-09 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
EP1477496A4 (en) 2002-02-01 2006-08-02 Chugai Pharmaceutical Co Ltd PEG-CONJUGATED PTH BZW. PEG-CONJUGATED PTH DERIVATIVE
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7332164B2 (en) 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
CA2843439A1 (en) 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
JP4133570B2 (ja) * 2003-05-15 2008-08-13 アルパイン株式会社 ナビゲーション装置
US7690003B2 (en) 2003-08-29 2010-03-30 Fuller Jeffrey C System and method for increasing data throughput using thread scheduling
US20070203058A1 (en) * 2003-09-19 2007-08-30 Novo Nordisk A/S Novel Glp-1 Derivatives
CN1657540A (zh) * 2004-02-18 2005-08-24 中国人民解放军军事医学科学院基础医学研究所 人甲状旁腺素（1－34）的聚乙二醇化衍生物，含有它们的药物组合物及用途
CA2824093C (en) * 2004-03-23 2016-10-25 Complex Biosystems Gmbh Polymeric prodrug with a self-immolative linker
US7244709B2 (en) 2004-05-10 2007-07-17 Nastech Pharamecutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
CN1597697A (zh) * 2004-07-19 2005-03-23 中国药科大学 一种人的甲状旁腺素1－34肽相关肽－Pro－Pro－[Arg11]]hPTH(1－34)－Pro－Pro
US20060069021A1 (en) 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
JP2008511611A (ja) 2004-08-30 2008-04-17 ルナメツド・インコーポレーテツド 治療用４−フェニル酪酸制御放出製剤
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
CN1298386C (zh) 2005-08-31 2007-02-07 上海交通大学 甲状旁腺激素缓释微球的制备方法
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
JP2009530307A (ja) 2006-03-15 2009-08-27 アルザ コーポレイション 骨減少症を予防し、または治療するための副甲状腺ホルモン薬の経皮送達のための装置、並びに方法
NO325064B1 (no) * 2006-07-06 2008-01-28 Tandberg Telecom As Kommunikasjonsklient
WO2008034122A2 (en) 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
PL2084183T3 (pl) 2006-10-13 2010-10-29 Lilly Co Eli Pegylowane pth jako modulatory receptora pth i ich zastosowania
US8101729B2 (en) 2007-03-19 2012-01-24 Henry Joseph Niemczyk Pegylated amino acid derivatives and the process to synthesize the same
WO2008124166A2 (en) 2007-04-09 2008-10-16 The Board Of Trustees Of The University Of Arkansas Fusion proteins of collagen-binding domain and parathyroid hormone
AU2008266448B2 (en) 2007-06-21 2013-06-13 Technische Universitat Munchen Biological active proteins having increased in vivo and/or vitro stability
EP2175878A4 (en) 2007-07-11 2014-12-03 Belrose Pharma Inc POLYMER DRUG DISPENSING SYSTEM WITH A MULTIPLE SUBSTITUTED AROMATIC PART
EP2052736A1 (en) 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
RS58948B1 (sr) * 2008-02-01 2019-08-30 Ascendis Pharma As Prolek koji sadrži linker koji se može sam odcepiti
CN102989001B (zh) 2008-04-29 2014-12-03 阿森迪斯药物生长障碍股份有限公司 Peg化的重组人生长激素化合物
US20110105413A1 (en) 2008-05-23 2011-05-05 Enzon Pharmaceuticals, Inc. Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
WO2009156481A1 (en) 2008-06-25 2009-12-30 Ascendis Pharma As Pegylated bnp
JP2012500284A (ja) 2008-08-19 2012-01-05 フェリング ベスローテン フェンノートシャップ ペプチド性ｐｔｈ受容体アゴニスト
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
EP2459228B1 (en) 2009-07-31 2020-03-04 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an insulin linker conjugate
US9173953B2 (en) 2009-07-31 2015-11-03 Ascendis Pharma As Prodrugs containing an aromatic amine connected by an amido bond to a linker
KR101770844B1 (ko) 2009-07-31 2017-08-23 아센디스 파마 에이에스 폴리에틸렌 글리콜 기반의 생분해성 수불용성 하이드로겔
MA33466B1 (fr) 2009-07-31 2012-07-03 Sanofi Aventis Deutschland Composition d'insuline à longue duree d'action
WO2011012723A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Injectable sustained release compositions comprising a pramipexole prodrug
WO2011012721A1 (en) 2009-07-31 2011-02-03 Ascendis Pharma As Carrier linked pramipexole prodrugs
WO2011042450A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Carrier linked paliperidone prodrugs
AU2010332958B2 (en) * 2009-12-15 2014-09-18 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
US20130030359A1 (en) 2010-01-22 2013-01-31 Ascendis Pharma A/S Dipeptide-based prodrug linkers for aromatic amine-containing drugs
WO2011089214A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Carrier-linked carbamate prodrug linkers
US20110229580A1 (en) 2010-03-22 2011-09-22 Indian Institute of Technology Bombay, School of Biosciences and Bioengineering Compositions and methods for nano-in-micro particles
EP4450523A3 (en) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
JP5964815B2 (ja) 2010-05-05 2016-08-03 プロリンクス リミテッド ライアビリティ カンパニー 固体担体からの放出制御薬物
DK2566335T3 (en) 2010-05-05 2016-10-03 Prolynx Llc Controlled release of active ingredients from macromolecular CONJUGATES
KR101900078B1 (ko) 2010-05-13 2018-09-18 더 제너럴 하스피탈 코포레이션 부갑상선 호르몬 아날로그 및 그의 용도
BR112012029577B1 (pt) 2010-05-21 2022-04-12 Xl-Protein Gmbh Conjugado de fármaco compreendendo polipeptídeos helicoidais randômicos prolina/alanina biossintéticos, e composição farmacêutica ou diagnóstica
US8865220B2 (en) 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
JP5594791B2 (ja) 2010-06-30 2014-09-24 Ｎｅｃソリューションイノベータ株式会社 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム
US20120040320A1 (en) 2010-08-13 2012-02-16 Nadeau Daniel A Injection Simulation Device and Methods Thereof
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
WO2013024048A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
EP2741738A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Sustained release composition of prostacyclin
EP2741782B1 (en) 2011-08-12 2020-05-06 Ascendis Pharma A/S Protein carrier-linked prodrugs
EP2741781A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Carrier-linked treprostinil prodrugs
US20140249093A1 (en) 2011-08-12 2014-09-04 Ascendis Pharma A/S Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages
WO2013036857A1 (en) 2011-09-07 2013-03-14 Prolynx Llc Sulfone linkers
HK1198357A1 (en) 2011-10-12 2015-04-10 Ascendis Pharma Ophthalmology Division A/S Prevention and treatment of ocular conditions
US8883862B2 (en) 2012-01-12 2014-11-11 Kaohsiung Medical University Method for controlled release of parathyroid hormone from cross-linked hyaluronic acid hydrogel
IN2014MN01470A (es) 2012-01-20 2015-04-17 Lupin Ltd
CA2868925C (en) 2012-04-25 2020-01-21 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
CA2883707A1 (en) * 2012-08-28 2014-03-06 The Governors Of The University Of Alberta Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods of making and using thereof
NZ706853A (en) 2012-10-11 2018-04-27 Ascendis Pharma Ophthalmology Div A/S Vegf neutralizing prodrugs for the treatment of ocular conditions
CN104781314B (zh) 2012-10-11 2017-11-14 阿森迪斯药物股份有限公司 水凝胶前药
JP6355636B2 (ja) * 2012-10-11 2018-07-11 アセンディス ファーマ エー／エス 関節の疾患の診断、予防及び治療
US20150250882A1 (en) 2012-10-17 2015-09-10 Novo Nordisk Health Care Ag Fatty Acid Acylated Amino Acids for Growth Hormone Delivery
US9913912B2 (en) 2012-12-07 2018-03-13 Ascendis Pharma A/S Carrier-linked prostanoid prodrugs
GB201303771D0 (en) 2013-03-04 2013-04-17 Midatech Ltd Nanoparticles peptide compositions
AU2014257745B2 (en) 2013-04-22 2018-10-04 Ascendis Pharma A/S Hydrogel-linked prodrugs releasing modified drugs
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
EP3054981B1 (en) 2013-10-08 2020-07-29 Ascendis Pharma A/S Protecting group comprising a purification tag
EP2868326A1 (en) 2013-11-04 2015-05-06 Université Pierre et Marie Curie (Paris 6) Peptide inhibitors of TEAD/YAP-TAZ interaction
US11633487B2 (en) 2014-08-06 2023-04-25 Ascendis Pharma A/S Prodrugs comprising an aminoalkyl glycine linker
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
RU2728656C2 (ru) 2015-01-09 2020-07-31 Асцендис Фарма Гроус Дизордерс А/С Cnp пролекарства
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EP4470613A3 (en) * 2016-03-01 2025-03-12 Ascendis Pharma Bone Diseases A/S Pth prodrugs
EP4223309A1 (en) * 2016-09-29 2023-08-09 Ascendis Pharma Growth Disorders A/S Combination therapy with controlled-release cnp agonists
MA46428B1 (fr) * 2016-09-29 2025-02-28 Ascendis Pharma Bone Diseases A/S Composés de pth à libération contrôlée
EP4218795A3 (en) 2016-09-29 2023-08-30 Ascendis Pharma Bone Diseases A/S Pth compounds with low peak-to-trough ratios
NZ751969A (en) 2016-09-29 2023-04-28 Ascendis Pharma Bone Diseases As Dosage regimen for a controlled-release pth compound
AR110299A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico
AU2019270464B2 (en) 2018-05-18 2024-09-26 Ascendis Pharma Bone Diseases A/S Starting dose of PTH conjugates
MX2021009370A (es) * 2019-02-11 2021-09-10 Ascendis Pharma Bone Diseases As Formulaciones farmaceuticas liquidas de conjugados de hormona paratiroidea.
KR20220128390A (ko) 2020-01-13 2022-09-20 아센디스 파마 본 디지즈 에이/에스 부갑상선기능저하증 치료

Also Published As

Publication number Publication date
CN109069659A (zh) 2018-12-21
CN109069659B (zh) 2022-04-19
IL260756B2 (en) 2023-09-01
KR102524255B1 (ko) 2023-04-20
IL301616A (en) 2023-05-01
IL301616B1 (en) 2025-01-01
EP4470613A2 (en) 2024-12-04
MA45809A (fr) 2019-01-09
US20220008516A1 (en) 2022-01-13
AU2025279737A1 (en) 2026-01-15
AU2022256158A1 (en) 2022-12-08
MX2022015755A (es) 2023-01-19
AU2023285850A1 (en) 2024-01-18
SG11201806092TA (en) 2018-08-30
RU2018134135A (ru) 2020-04-01
US20250268988A1 (en) 2025-08-28
KR20180118197A (ko) 2018-10-30
LTPA2025506I1 (es) 2025-02-25
AU2017227962B2 (en) 2020-11-12
ZA201805705B (en) 2019-06-26
RS66250B1 (sr) 2024-12-31
HUS2500009I1 (hu) 2025-02-28
US20200376089A1 (en) 2020-12-03
KR102331820B1 (ko) 2021-11-29
MY196308A (en) 2023-03-24
AU2023285850B2 (en) 2025-09-18
FR24C1045I1 (fr) 2025-01-10
CN115025239B (zh) 2025-03-21
KR20230015517A (ko) 2023-01-31
PL3423103T3 (pl) 2025-02-10
AU2017227962C1 (en) 2021-05-13
NZ745318A (en) 2023-01-27
IL260756A (es) 2018-09-20
FI3423103T3 (fi) 2024-11-20
JP7059195B2 (ja) 2022-04-25
JP2019513127A (ja) 2019-05-23
RU2747316C2 (ru) 2021-05-04
HRP20241591T1 (hr) 2025-02-28
WO2017148883A1 (en) 2017-09-08
AU2020286303B2 (en) 2022-07-21
IL260756B1 (en) 2023-05-01
JP2022068210A (ja) 2022-05-09
HUE069445T2 (hu) 2025-03-28
NL301298I2 (nl) 2024-12-11
NO2025005I1 (no) 2025-01-14
MA45809B1 (fr) 2024-12-31
US20200360487A1 (en) 2020-11-19
RU2018134135A3 (es) 2020-04-01
AU2020286303A1 (en) 2021-02-04
IL301616B2 (en) 2025-05-01
ES2993932T3 (en) 2025-01-14
AU2022256158A9 (en) 2023-09-28
KR20210147085A (ko) 2021-12-06
SMT202400423T1 (it) 2024-11-15
AU2022256158B2 (en) 2023-09-28
CA3015585C (en) 2025-09-23
US20200276276A1 (en) 2020-09-03
IL317744A (en) 2025-02-01
US11793861B2 (en) 2023-10-24
FIC20250008I1 (fi) 2025-02-03
KR102786270B1 (ko) 2025-03-24
MY208384A (en) 2025-05-05
BR112018017091A2 (pt) 2019-01-02
JP2025000652A (ja) 2025-01-07
AU2017227962A1 (en) 2018-08-09
EP3423103A1 (en) 2019-01-09
CN115025239A (zh) 2022-09-09
LT3423103T (lt) 2024-10-25
NZ785623A (en) 2024-10-25
EP4470613A3 (en) 2025-03-12
MA45277A (fr) 2019-01-09
AU2020286303C1 (en) 2023-03-02
CA3015585A1 (en) 2017-09-08
US20240123038A1 (en) 2024-04-18
DK3423103T3 (da) 2024-09-30
US20230121525A1 (en) 2023-04-20
FR24C1045I2 (fr) 2025-10-10
EP3423103B1 (en) 2024-09-11
SI3423103T1 (sl) 2024-12-31
KR20250044469A (ko) 2025-03-31
JP7619973B2 (ja) 2025-01-22
US12214020B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
MX2018009938A (es) Profarmacos de hormona paratiroidea (pth).
BR112018006471A2 (pt) compostos úteis como moduladores de trpm8
ECSP18040758A (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos
SV2018005684A (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
MX2018007987A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
MX2019009361A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
BR112019004785A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
DOP2017000298A (es) Reguladores de nrf2
BR112018010118A2 (pt) inibidores de cxcr2
CL2016002772A1 (es) Composiciones de insulina de rápida acción
BR112017006137A2 (pt) formulação que contém biotensoativo
BR112019004783A2 (pt) variantes de alfa-glicosidase ácida e usos das mesmas
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
BR112018009120A2 (pt) métodos de formação de compostos contendo aromáticos
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
DOP2017000260A (es) Piroglutamato de vortioxetina
MX388186B (es) Granos de gluten reducido y composiciones de los mismos.
GT201600252A (es) Derivados de naftiridinadiona
BR112016028192A2 (pt) gerritdina g. schoonus-gerritsma
ES1216222Y (es) Composicion que comprende cenizas de cremacion
MX2021004581A (es) Composiciones acuosas que comprenden omega nitrooxi-1-alcanoles.
CL2017000645A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
CL2016003351A1 (es) Lipido que comprende ácido docosapentanoico
BR112017028361A2 (pt) 2,4,7-trimetiloct-6-en-1-ol como ingrediente de fragrância
BR112017000908A2 (pt) sal de tenofovir disoproxil